Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.
Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. Pope MK, et al. Among authors: le heuzey jy. BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450. BMJ. 2021. PMID: 34706884 Free PMC article.
Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
Le Heuzey JY, Bassand JP, Berneau JB, Cozzolino P, D'Angiolella L, Doucet B, Mantovani LG, Martelet M, Mouallem J, Muller JJ, Pieper K; GARFIELD-AF Investigators. Le Heuzey JY, et al. Arch Cardiovasc Dis. 2018 Dec;111(12):749-757. doi: 10.1016/j.acvd.2018.03.012. Epub 2018 Jun 1. Arch Cardiovasc Dis. 2018. PMID: 29861295 Free article.
Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.
Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey JY, Steffel J, Stepinska J, Bassand JP, Camm AJ; GARFIELD-AF Investigators. Pope MK, et al. Among authors: le heuzey jy. Ann Med. 2021 Dec;53(1):485-494. doi: 10.1080/07853890.2021.1893897. Ann Med. 2021. PMID: 33818226 Free PMC article.
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca MI, Vardas PE, Kirchhof P, Hohnloser SH, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M. Ezekowitz MD, et al. Among authors: le heuzey jy. Am Heart J. 2014 May;167(5):646-52. doi: 10.1016/j.ahj.2013.12.024. Epub 2014 Jan 14. Am Heart J. 2014. PMID: 24766973 Clinical Trial.
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Cappato R, et al. Among authors: le heuzey jy. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2. Eur Heart J. 2014. PMID: 25182247 Clinical Trial.
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.
Haas S, Camm JA, Harald D, Steffel J, Virdone S, Pieper K, Brodmann M, Schellong S, Misselwitz F, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Haas S, et al. Clin Res Cardiol. 2023 Jun;112(6):759-771. doi: 10.1007/s00392-022-02079-y. Epub 2022 Sep 12. Clin Res Cardiol. 2023. PMID: 36094573
Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey).
Erküner Ö, Dudink EAMP, Nieuwlaat R, Rienstra M, Van Gelder IC, Camm AJ, Capucci A, Breithardt G, LeHeuzey JY, Lip GYH, Crijns HJGM, Luermans JGLM. Erküner Ö, et al. Am J Cardiol. 2018 Aug 15;122(4):578-583. doi: 10.1016/j.amjcard.2018.04.053. Epub 2018 May 11. Am J Cardiol. 2018. PMID: 29958714 Free article.
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.
Renda G, Pecen L, Patti G, Ricci F, Kotecha D, Siller-Matula JM, Schnabel RB, Wachter R, Sellal JM, Rohla M, Lucerna M, Huber K, Verheugt FWA, Zamorano JL, Brüggenjürgen B, Darius H, Duytschaever M, Le Heuzey JY, Schilling RJ, Kirchhof P, De Caterina R. Renda G, et al. Among authors: le heuzey jy. Intern Emerg Med. 2021 Apr;16(3):591-599. doi: 10.1007/s11739-020-02442-9. Epub 2020 Sep 21. Intern Emerg Med. 2021. PMID: 32955677 Free PMC article.
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Naccarelli GV, Bhatt DL, Camm AJ, Le Heuzey JY, Lombardi F, Tamargo J, Martinez JM, Naditch-Brûlé L; ARTEMIS AF Investigators. Naccarelli GV, et al. Among authors: le heuzey jy. J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):425-437. doi: 10.1177/1074248420926874. Epub 2020 Jun 5. J Cardiovasc Pharmacol Ther. 2020. PMID: 32500725 Free PMC article. Clinical Trial.
278 results